
Keyword: BRCA1
https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer
Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent
Clinicaltrials.gov identifier:
NCT06844383 (https://clinicaltrials.gov/show/NCT06844383)
Treatment
Study for metastatic castration-resistant prostate cancer with an HRR mutation
https://www.facingourrisk.org/research-clinical-trials/study/266 /helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Clinicaltrials.gov identifier:
NCT07318363 (https://clinicaltrials.gov/show/NCT07318363)
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
https://www.facingourrisk.org/research-clinical-trials/study/435 /previvors-perceptions-of-preimplantation-genetic-testing-pgt-m-after-a-cancer-predisposition-diagnosis
Surveys, Registries, Interviews
Interview for eligible previvors
https://www.facingourrisk.org/research-clinical-trials/study/450 /beyond-a-womens-gene-assessing-the-perception-and-satisfaction-following-genetic-counseling-for-male-brca-carriers
Surveys, Registries, Interviews
Survey for men with a BRCA1 or BRCA2 genetic mutation
https://www.facingourrisk.org/research-clinical-trials/study/332 /understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations
Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of cancer
https://www.facingourrisk.org/research-clinical-trials/study/428 /family-study-for-people-with-certain-rare-brca1-or-brca2-variants
Surveys, Registries, Interviews
Family study for adults with a known rare BRCA1 or BRCA2 variant in themselves or a relative
https://www.facingourrisk.org/research-clinical-trials/study/439 /comparing-investigational-drug-combination-sacituzumab-govitecan-with-bevacizumab-to-chemotherapy-for-treating-recurrent-ovarian-cancer-after-parp-inhibitor-maintenance-therapy
Clinicaltrials.gov identifier:
NCT07504588 (https://clinicaltrials.gov/show/NCT07504588)
Treatment
Study for platinum-sensitive ovarian cancer that has progressed after PARP inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8
Clinicaltrials.gov identifier:
NCT06395519 (https://clinicaltrials.gov/show/NCT06395519)
Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
https://www.facingourrisk.org/research-clinical-trials/study/392 /evaluating-the-safety-of-nipple-sparing-mastectomy-in-women-with-a-high-risk-for-breast-cancer
Clinicaltrials.gov identifier:
NCT06888388 (https://clinicaltrials.gov/show/NCT06888388)
Prevention
Study for people considering double mastectomy to reduce breast cancer risk
https://www.facingourrisk.org/research-clinical-trials/study/404 /
Clinicaltrials.gov identifier:
NCT04294927 (https://clinicaltrials.gov/show/NCT04294927)
Prevention
Prevention study for women at high risk for ovarian cancer
https://www.facingourrisk.org/research-clinical-trials/study/353 /using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT05384535 (https://clinicaltrials.gov/show/NCT05384535)
Prevention
Screening for people at high risk for prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/361 /testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd
Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
https://www.facingourrisk.org/research-clinical-trials/study/369 /a-study-of-the-parp-inhibitor-saruparib-added-to-standard-treatment-for-high-risk-brca1-positive-prostate-cancer
Clinicaltrials.gov identifier:
NCT06952803 (https://clinicaltrials.gov/show/NCT06952803)
Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/349 /studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Clinicaltrials.gov identifier:
NCT06380751 (https://clinicaltrials.gov/show/NCT06380751)
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/101 /a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.